Nurix Therapeutics Inc
$ 15.38
-2.53%
23 Feb - close price
- Market Cap 1,581,725,000 USD
- Current Price $ 15.38
- High / Low $ 16.49 / 15.29
- Stock P/E N/A
- Book Value 5.29
- EPS -3.05
- Next Earning Report 2026-04-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.50 %
- 52 Week High 22.50
- 52 Week Low 8.18
About
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California.
Analyst Target Price
$30.00
Quarterly Earnings
| Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | Aug 2023 | May 2023 | Feb 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-28 | 2025-10-09 | 2025-07-09 | 2025-04-08 | 2025-02-13 | 2024-10-11 | 2024-07-11 | 2024-04-10 | 2024-02-15 | 2023-10-12 | 2023-07-13 | 2023-04-13 |
| Reported EPS | -0.82 | -1.03 | -0.52 | -0.67 | -0.75 | -0.67 | -0.71 | -0.76 | -0.77 | -0.68 | -0.45 | -0.75 |
| Estimated EPS | -0.92 | -0.83 | -0.714 | -0.7614 | -0.6689 | -0.71 | -0.63 | -0.8 | -0.57 | -0.76 | -0.56 | -0.87 |
| Surprise | 0.1 | -0.2 | 0.194 | 0.0914 | -0.0811 | 0.04 | -0.08 | 0.04 | -0.2 | 0.08 | 0.11 | 0.12 |
| Surprise Percentage | 10.8696% | -24.0964% | 27.1709% | 12.0042% | -12.1244% | 5.6338% | -12.6984% | 5% | -35.0877% | 10.5263% | 19.6429% | 13.7931% |
Next Quarterly Earnings
| Feb 2026 | |
|---|---|
| Reported Date | 2026-04-14 |
| Fiscal Date Ending | 2026-02-28 |
| Estimated EPS | -0.76 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NRIX
2026-02-22 18:58:43
Redmile Group increased its stake in Nurix Therapeutics (NASDAQ:NRIX) by $63.43 million, despite the stock being down 6% over the past year. This significant investment makes Nurix Therapeutics the third-largest holding in Redmile Group’s portfolio, representing 11.31% of its AUM. The move comes as Nurix advances its lead BTK degrader into a registrational program, hinting at potential future growth despite current stock volatility and substantial R&D spending.
2026-02-15 08:57:47
This article provides an analysis of Nurix Therapeutics Inc. (NASDAQ: NRIX), highlighting weak near and mid-term sentiment that could challenge a positive long-term outlook. Key findings include resistance being tested, and an exceptional risk-reward short setup. The article details institutional trading strategies with entry points, targets, and stop losses for position trading, momentum breakout, and risk hedging.
2026-02-14 16:27:27
Nurix Therapeutics is emphasizing its immunology and inflammation pipeline, which leverages targeted protein degraders for STAT6, BTK, and IRAK4. The company argues that degraders offer advantages over traditional inhibitors by removing the entire protein, addressing non-enzymatic scaffolding functions, and enabling targeting of difficult-to-drug proteins like STAT6. Key programs include the STAT6 degrader NX-3911 (partnered with Sanofi), a BTK degrader (bexobrutideg) in a tablet formulation for autoimmune uses, and an IRAK4 degrader partnered with Gilead, with significant updates anticipated for 2026.
2026-02-13 16:57:47
Nurix Therapeutics (NRIX) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and inflammatory conditions. Despite being unprofitable with a negative P/E ratio and EPS, analysts are highly optimistic, setting an average target price of $30.00, representing a 90.72% potential upside. The company's promising drug pipeline and strategic partnerships with industry giants like Gilead Sciences and Pfizer support this positive outlook, though investors should be aware of the inherent risks and volatility in the biotech sector.
2026-02-10 05:27:32
Nurix Therapeutics (NRIX) reported full-year 2025 earnings with increased revenue but a wider net loss, alongside a new shelf registration. The company's stock has seen recent volatility, and its Price-to-Sales ratio of 20.6x is considered overvalued compared to industry averages and an estimated fair value. This valuation suggests that significant execution will be required to support the current share price, especially given the company's unprofitability and reliance on early-stage trials.
2026-02-06 03:59:30
Nurix Therapeutics experienced a 7.4% stock decline following its full-year 2025 report, which showed increased revenue but also a wider net loss of US$264.46 million and a significant shelf registration for common shares. The company is advancing its lead drug, bexobrutideg, into pivotal development, supported by key partnerships, yet investors are focused on the widening losses and potential for share dilution. The article suggests Nurix's stock might be overvalued despite community consensus targets.
